摘要
目的观察联合应用布地奈德鼻喷剂和地氯雷他定片治疗过敏性鼻炎的临床疗效和安全性。方法将该院门诊2010年3月—2012年3月诊断为过敏性鼻炎的患者126例随机分为3组,观察组42例,给予布地奈德鼻喷剂联合地氯雷他定片治疗,对照A组42例,单用布地奈德鼻喷剂治疗,对照B组42例,单用地氯雷他定片治疗。疗程2周,记录3组治疗前后的症状评分并进行比较。结果观察组总有效率为92.8%,明显优于对照A组的73.8%和对照B组的66.7%(P<0.05),且三者不良反应发生率差异无统计学意义(P>0.05)。结论联合应用布地奈德鼻喷剂和地氯雷他定片治疗过敏性鼻炎疗效优于单用一种药物,且没有明显不良反应,值得临床推广使用。
Objective To observe the clinical efficacy and safety of allergic rhinitis with combination of budesonide nasal spray and Loratadine tablets. Method 126 cases of allergic rhinitis patients in our clinic from March 2010 to March 2012 were given randomly divided into three groups, 42 patients of the observation group, were given budesonide nasal spray jointly loratadine tablets in the treatment. 42 patients of control A group, were simply given budesonide nasal spray, 42 cases of control group B were simply given desloratadine tablets in the treatment. Symptom scores of the three groups were record and compared two weeks＇ s later before and after treatment. Results The total effective rate was 92.8% in the observation group, significantly better than the control group A 73.8% and the and control group B 66.7% （P 〈0.05）, and the three incidence of adverse reactions were not significant different （P 〉 0.05）. Conclusion The combination of budesonide nasal spray and Desloratadine tablets on allergic rhinitis is more effective than the single drug,and there is no significant adverse reactions, is worthy of clinical use.
出处
《中国卫生产业》
2012年第34期27-28,共2页
China Health Industry
